USPTO Art Unit 1656 Prosecution Statistics

Art Unit Information

Art Unit: 1656
Group: 1650
Tech Center: 1600
Total Cases: 13,539
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18879948NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAMEDecember 2024June 2025Allow600YesNo
18879995NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5�-INOSINIC ACID USING SAMEDecember 2024May 2025Allow500NoNo
18984162CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATIONDecember 2024May 2025Allow500YesNo
18970552S. PYOGENES CAS9 MUTANT GENES AND POLYPEPTIDES ENCODED BY SAMEDecember 2024May 2025Allow510NoNo
18870088METHOD FOR PRODUCING GUANIDINO ACETIC ACID (GAA)November 2024February 2025Allow300YesNo
18926774PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOFOctober 2024May 2025Allow621NoNo
18919946FUSION POLYPEPTIDES FOR PRODUCTION OF 7-DEHYDROCHOLESTEROL AND METHODS OF USE THEREOFOctober 2024February 2025Allow401NoNo
18894709Compositions and Methods for Making Epigenetic ModificationsSeptember 2024March 2025Allow510YesNo
18886925HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEINSeptember 2024January 2025Allow410YesNo
18847017SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDESSeptember 2024February 2025Allow500YesNo
18882318RECOMBINANT CELL WALL HYDROLASESSeptember 2024December 2024Allow301NoNo
18824681PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESSeptember 2024November 2024Allow200YesNo
18755691Fusion protein and its preparation method for intermediate polypeptide of SemaglutideJune 2024November 2024Allow510YesNo
18723639NOVEL PROMOTER VARIANT FOR CONSTITUTIVE EXPRESSION AND USES THEREOFJune 2024April 2025Allow1001YesNo
18721879ZAVARZINIA COMPRANSORIS CAPABLE OF DEGRADING ORGANOPHOSPHORUS FLAME RETARDANT AND USE THEREOFJune 2024June 2025Allow1200YesNo
18747818Peptides for Characterization of Botulinum NeurotoxinsJune 2024March 2025Allow910NoNo
18734239METHOD FOR EXPANDING PROPAGATION OF METARHIZIUM RILEYI MR006 AND USE THEREOFJune 2024April 2025Allow1020NoNo
18731571IMMOBILIZED ENZYMES FOR BIOELECTROCATALYSISJune 2024July 2025Allow1311YesNo
18662446Enzyme Variants With Improved Ester Synthase PropertiesMay 2024April 2025Allow1110YesNo
18648034PROCESSES AND SYSTEMS TO PRODUCE RENEWABLE ENERGY AND FIBER FROM CELLULOSE-RICH WASTE MATERIALSApril 2024April 2025Allow1111NoNo
18648209PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESApril 2024August 2024Allow300YesNo
18626782ENGINEERING STRAIN PRODUCING CORDYCEPIN AND ITS DERIVATIVE 3'-DEOXYINOSINE, ITS PREPARATION METHOD AND APPLICATIONApril 2024March 2025Allow1111YesNo
18625448ALDEHYDE DEHYDROGENASE PRODUCING BACTERIA AND METHODS OF USING SAMEApril 2024July 2024Allow300YesNo
18614748Construction Method and Applications of Glycosyltransferase BS-YjiC MutantMarch 2024September 2024Allow502YesNo
18615341BOTULINUM NEUROTOXIN BIOHYBRIDMarch 2024June 2025Abandon1501NoNo
18614665BONE GELATIN PROCESSMarch 2024August 2024Allow410NoNo
18612615METHODS AND COMPOSITIONS FOR THE ENZYMATIC PRODUCTION OF PSEUDOURIDINE TRIPHOSPHATEMarch 2024January 2025Allow1011YesNo
18693613METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING C. GLUTAMICUM STRAINS EXPRESSING MODIFIED GLUCONATE REPRESSOR PROTEINS GNTR1 AND GNTR2March 2024December 2024Allow920YesNo
18600332ENZYMATIC METHOD FOR PREPARING REBAUDIOSIDE JMarch 2024April 2025Abandon1310NoNo
18598993METHODS FOR RAPID SEPARATION AND PURIFICATION OF DNA TOPOLOGICAL FORMSMarch 2024March 2025Allow1210NoNo
18598286Methods and Systems for Determining ADAMTS13 Enzyme ActivityMarch 2024June 2025Allow1501YesNo
18595600ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEMarch 2024May 2025Allow1401YesNo
18688056POLYPEPTIDES AND USES THEREOFFebruary 2024May 2025Allow1411NoNo
18586709Polypeptides having Peptidoglycan Degrading Activity and Polynucleotides Encoding SameFebruary 2024January 2025Allow1100YesNo
18586929ENZYMES WITH RUVC DOMAINSFebruary 2024December 2024Allow921NoNo
18584363PD-1 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USEFebruary 2024March 2025Allow1310NoNo
18582803Chimeric endolysin polypeptideFebruary 2024July 2024Allow500YesNo
18444590Compositions and Methods for Making Epigenetic ModificationsFebruary 2024June 2024Allow400YesNo
18438285CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOFFebruary 2024April 2025Allow1410YesNo
18432802VARIANT LOVD POLYPEPTIDES AND THEIR USESFebruary 2024March 2025Allow1411NoNo
18432505MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYFebruary 2024March 2025Allow1300YesNo
18431662RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEFebruary 2024February 2025Allow1300YesNo
18428104Recombinant Escherichia Coli for Producing L-tyrosine and Application ThereofJanuary 2024May 2025Allow1621NoNo
18424952MODIFIED IMMUNE CELLS HAVING ENHANCED FUNCTION AND METHODS FOR SCREENING THE SAMEJanuary 2024January 2025Allow1100YesNo
18419368HARVEST OPERATIONS FOR RECOMBINANT PROTEINSJanuary 2024March 2025Abandon1301NoNo
18417919METHODS, DEVICES, AND KITS FOR PURIFYING AND LYSING BIOLOGICAL PARTICLESJanuary 2024April 2025Abandon1511NoNo
18416843ICAM-1 TARGETED FUSION ENZYMESJanuary 2024February 2025Allow1300YesNo
18416306POLYMERASE ENZYME FROM PHAGE T4January 2024April 2025Abandon1501NoNo
18410949PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024April 2024Allow300YesNo
18410876PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDESJanuary 2024March 2024Allow200YesNo
18405861PROTEASE VARIANTS AND USES THEREOFJanuary 2024July 2024Allow710YesNo
18405674VARIANT MALTOHEXAOSE-FORMING ALPHA-AMYLASE VARIANTSJanuary 2024February 2025Allow1300YesNo
18404392DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASESJanuary 2024February 2025Allow1310NoNo
18401511RECOMBINANT ZYMOMONAS MOBILIS FOR PRODUCING ETHYLENE GLYCOL, METHOD AND USES THEREOFDecember 2023July 2024Allow710YesNo
18398650FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIADecember 2023April 2025Allow1621YesNo
18394404METHODS FOR PURIFICATION OF ARYLSULFATASE ADecember 2023January 2025Allow1310NoNo
18392928COMPOSITIONS AND METHODS FOR CONTROLLED MRNA TRANSLATION AND STABILITYDecember 2023June 2025Allow1721YesNo
18390011APPARATUS AND METHODS USING TETHERED ENZYMES FOR THE DETECTION OF THE ENZYMATIC ACTIVITY OF BIOMARKERSDecember 2023April 2025Abandon1611NoNo
18390884MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERYDecember 2023May 2024Allow500YesNo
18544368TYPE III COLLAGEN PEPTIDE AND PREPARATION METHOD THEREOFDecember 2023June 2024Allow610NoNo
18532665SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOFDecember 2023April 2025Abandon1610NoNo
18525460HUMANIZED CELL LINENovember 2023October 2024Allow1100YesNo
18520960PICHIA PASTORIS STRAINS FOR PRODUCING PREDOMINANTLY HOMOGENEOUS GLYCAN STRUCTURENovember 2023March 2025Allow1510YesNo
18515733CYSTEINE POLYSULFIDATION AND MITOCHONDRIAL BIOENERGETICS REGULATED BY CYSTEINYL-tRNA SYNTHETASENovember 2023December 2024Abandon1310NoNo
18516160SOLUBILIZATION OF MSW WITH BLEND ENZYMESNovember 2023March 2025Abandon1601NoNo
18514046SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTIONNovember 2023January 2025Abandon1310NoNo
18513744TARDIGRADE DISORDERED PROTEINS AS PROTEIN STABILIZERSNovember 2023February 2025Abandon1501NoNo
18561170IDENTIFICATION OF AN alpha-1,2-FUCOSYLTRANSFERASE FOR THE IN VIVO PRODUCTION OF PURE LNFP-INovember 2023June 2025Allow1911YesNo
18505972ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOFNovember 2023February 2025Allow1510YesNo
18504590MUTANT LYSENIN PORESNovember 2023November 2024Allow1210YesNo
18503341NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOFNovember 2023February 2025Abandon1510NoNo
18502499CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATIONNovember 2023September 2024Allow1000NoNo
18502473TOXIN-DERIVED DELIVERY CONSTRUCTSNovember 2023February 2025Abandon1610NoNo
18558849Optimization of a Thermophilic PHB Depolymerase for Industrial ApplicationsNovember 2023June 2025Allow2021YesNo
18386621Mutant Taq Polymerase Providing Faster AmplificationNovember 2023February 2025Allow1500YesNo
18496409EXTENDED METABOLISM METHODS FOR INCREASING AND EXTRACTING METABOLITES FROM ALGAE AND MICROORGANISMSOctober 2023May 2024Allow721YesNo
18489954Agarase Mutant with Improved Thermal Stability and Application ThereofOctober 2023April 2024Allow610NoNo
18287223PROTEIN COMPLEX INCLUDING BOTULINUM TOXIN TRANSLOCATION DOMAIN AND ENDOLYSIN AND ANTIBACTERIAL COMPOSITION INCLUDING SAMEOctober 2023August 2024Allow1020YesNo
18486403COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIESOctober 2023January 2025Abandon1510NoNo
18484844TRIPLE SYRINGE AND METHODS OF MAKING PLATELET-ENRICHED PLASMA AND USE THEREOFOctober 2023September 2024Allow1210YesNo
18484305BLOOD GLUCOSE STABILIZING METHODS AND COMPOSITIONSOctober 2023March 2025Abandon1810NoNo
18481086INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOFOctober 2023February 2025Allow1610NoNo
18476753NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITYSeptember 2023March 2025Allow1811YesNo
18474786GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDSSeptember 2023June 2024Allow911NoNo
18473990COMPOSITIONS AND METHODS FOR EPIGENETIC REGULATION OF HBV GENE EXPRESSIONSeptember 2023February 2025Abandon1721NoNo
18472540KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONESeptember 2023August 2024Allow1110YesNo
18471524ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSSeptember 2023March 2025Allow1711YesNo
18471901OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USESeptember 2023June 2025Allow2010YesNo
18470985BIOMARKER ASSAY FOR USE IN MONITORING AUTISMSeptember 2023February 2025Allow1710NoNo
18469527D-AMINO ACID OXIDASE MUTANTS AND USES THEREOF IN PREPARING L-GLUFOSINATESeptember 2023April 2024Allow701YesNo
18467616SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELDSeptember 2023April 2025Abandon1911YesNo
18464514DETERGENT COMPOSITIONS AND USES THEREOFSeptember 2023April 2025Abandon1921NoNo
18463864HOST CELLS COMPRISING A RECOMBINANT CASEIN PROTEIN AND A RECOMBINANT KINASE PROTEINSeptember 2023August 2024Allow1121NoNo
18462921NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOFSeptember 2023September 2024Abandon1211NoNo
18461658EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFORESeptember 2023October 2024Abandon1310NoNo
18456894SECONDARY ACETATE FERMENTATIONAugust 2023May 2025Abandon2101NoNo
18456333RECOMBINANT YEAST AND USE THEREOFAugust 2023January 2025Allow1711YesNo
18455969GERANYLGERANYL PYROPHOSPHATE SYNTHASESAugust 2023June 2025Abandon2221YesNo
18454874METHOD FOR PRODUCING SEDOHEPTULOSEAugust 2023March 2025Allow1930YesNo
18454701COMPOSITIONS AND METHODS FOR TREATMENT OF HOMOCYSTINURIAAugust 2023September 2024Allow1200YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1656.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
123
Examiner Affirmed
81
(65.9%)
Examiner Reversed
42
(34.1%)
Reversal Percentile
58.4%
Higher than average

What This Means

With a 34.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1006
Allowed After Appeal Filing
225
(22.4%)
Not Allowed After Appeal Filing
781
(77.6%)
Filing Benefit Percentile
9.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1656 - Prosecution Statistics Summary

Executive Summary

Art Unit 1656 is part of Group 1650 in Technology Center 1600. This art unit has examined 13,539 patent applications in our dataset, with an overall allowance rate of 64.6%. Applications typically reach final disposition in approximately 30 months.

Comparative Analysis

Art Unit 1656's allowance rate of 64.6% places it in the 19% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1656 receive an average of 1.68 office actions before reaching final disposition (in the 37% percentile). The median prosecution time is 30 months (in the 41% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.